108 related articles for article (PubMed ID: 31631753)
21. Expression of cell-cycle regulator p27 is correlated to the prognosis and ER expression in breast carcinoma patients.
Nohara T; Ryo T; Iwamoto S; Gon G; Tanigawa N
Oncology; 2001; 60(1):94-100. PubMed ID: 11150915
[TBL] [Abstract][Full Text] [Related]
22. p53, Ki67 and cyclin D1 as prognosticators of lymph node metastases in laryngeal carcinoma.
Mielcarek-Kuchta D; Olofsson J; Golusinski W
Eur Arch Otorhinolaryngol; 2003 Nov; 260(10):549-54. PubMed ID: 14551784
[TBL] [Abstract][Full Text] [Related]
23. Cyclin D1 is significantly associated with stage of tumor and predicts poor survival in endometrial carcinoma patients.
Khabaz MN; Abdelrahman AS; Butt NS; Al-Maghrabi B; Al-Maghrabi J
Ann Diagn Pathol; 2017 Oct; 30():47-51. PubMed ID: 28965628
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical labelling for prostate-specific antigen in breast carcinomas.
Alanen KA; Kuopio T; Collan YU; Kronqvist P; Juntti L; Nevalainen TJ
Breast Cancer Res Treat; 1999 Jul; 56(2):169-76. PubMed ID: 10573109
[TBL] [Abstract][Full Text] [Related]
25. Cyclin D1 in breast cancer.
Barnes DM; Gillett CE
Breast Cancer Res Treat; 1998; 52(1-3):1-15. PubMed ID: 10066068
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
Abdelrahman AE; Fathy A; Elsebai EA; Nawar N; Etman WM
Ann Diagn Pathol; 2018 Aug; 35():27-37. PubMed ID: 30072015
[TBL] [Abstract][Full Text] [Related]
27. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
[TBL] [Abstract][Full Text] [Related]
28. The validity of immunocytochemical expression of cyclin D1 in fine needle aspiration cytology of breast carcinoma.
Ezzat N; Hafez N
J Egypt Natl Canc Inst; 2012 Sep; 24(3):145-50. PubMed ID: 22929921
[TBL] [Abstract][Full Text] [Related]
29. Cyclin D1-CDK4 complex, a possible critical factor for cell proliferation and prognosis in laryngeal squamous cell carcinomas.
Dong Y; Sui L; Sugimoto K; Tai Y; Tokuda M
Int J Cancer; 2001 Jul; 95(4):209-15. PubMed ID: 11400112
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients.
Hwang TS; Han HS; Hong YC; Lee HJ; Paik NS
Pathol Int; 2003 Feb; 53(2):74-80. PubMed ID: 12588434
[TBL] [Abstract][Full Text] [Related]
31. Nuclear loss of protein arginine N-methyltransferase 2 in breast carcinoma is associated with tumor grade and overexpression of cyclin D1 protein.
Zhong J; Cao RX; Liu JH; Liu YB; Wang J; Liu LP; Chen YJ; Yang J; Zhang QH; Wu Y; Ding WJ; Hong T; Xiao XH; Zu XY; Wen GB
Oncogene; 2014 Nov; 33(48):5546-58. PubMed ID: 24292672
[TBL] [Abstract][Full Text] [Related]
32. [Expression of ER, PR and cyclin D1 in breast infiltrating ductal carcinoma and their clinicopathological significance].
Wang ZB; Zhao P; Liu M; Li XH
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(8):514-7. PubMed ID: 15949328
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor.
Takagi Y; Takashi M; Koshikawa T; Sakata T; Ohshima S
Int J Urol; 2000 Oct; 7(10):366-72. PubMed ID: 11144504
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological and prognostic significance of cyclin D1 amplification in patients with breast cancer: a meta-analysis.
He Q; Wu J; Liu XL; Ma YH; Wu XT; Wang WY; An HX
J BUON; 2017; 22(5):1209-1216. PubMed ID: 29135104
[TBL] [Abstract][Full Text] [Related]
35. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen may serve as a pathological predictor in breast cancer.
Nariţa D; Anghel A; Motoc M
Rom J Morphol Embryol; 2008; 49(2):173-80. PubMed ID: 18516323
[TBL] [Abstract][Full Text] [Related]
37. Expression of p53, p16, cyclin D1, epidermal growth factor receptor and Notch1 in patients with temporal bone squamous cell carcinoma.
Morita S; Nakamaru Y; Homma A; Yasukawa S; Hatakeyama H; Sakashita T; Kano S; Fukuda A; Fukuda S
Int J Clin Oncol; 2017 Feb; 22(1):181-189. PubMed ID: 27488595
[TBL] [Abstract][Full Text] [Related]
38. Cyclin D1 expression in prostate carcinoma.
Pereira RA; Ravinal RC; Costa RS; Lima MS; Tucci S; Muglia VF; Reis RB; Silva GE
Braz J Med Biol Res; 2014 Jun; 47(6):515-21. PubMed ID: 24820071
[TBL] [Abstract][Full Text] [Related]
39. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma.
Kallakury BV; Sheehan CE; Ambros RA; Fisher HA; Kaufman RP; Ross JS
Cancer; 1997 Aug; 80(4):753-63. PubMed ID: 9264360
[TBL] [Abstract][Full Text] [Related]
40. [High expression of cyclin D1 is correlated with the expression of estrogen receptor and good prognosis in breast cancer].
Yang C; Nan K; Zhang Y; Chen Y; Qin S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jan; 32(1):84-7. PubMed ID: 26728382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
